Swiftsure International Inc.
Holmes Biopharma : Commences European Operations

Holmes Biopharma Inc. / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Holmes Biopharma :  Commences European Operations

August 8, 2007 – (Scottsdale, Arizona)  Holmes Biopharma Inc. (Berlin Stock
Exchange symbol HHJA, security code A0KDRX) is pleased to announce that
it’s clinical research subsidiary, Qualia Clinical Service, has now
established an operational Phase I clinic in Kiev, Ukraine. This gives the
company a physical presence in both North America and Europe.
 
According to Pharmafocus, over the past decade the number of multi-center
clinical trials in the Central and Eastern Europe (CEE) region has been
growing on average at a rate of 30%. With a population in excess of 270
million, Eastern Europe has a huge potential for clinical trials ' said Dr.
Sohail Khattak, President CEO of Qualia Clinical Services. Dr Khattak also
stated that 'Due to its clinical trial infrastructure, suitable patient
populations and medical expertise, our presence in Eastern Europe will
provide HolmesBiopharma with tremendous growth opportunities '.

Analysts, Frost & Sullivan predict, by the end of 2007 the market will be
worth an estimated $4.3 Billion, primarily driven by the increasing
attractiveness of Eastern Europe to drug developers in both the US and
Western Europe.

 About Holmes:
Holmes Biopharma Inc. and it’s wholly owned subsidiary, Qualia Clinical
Service, Inc. is a contract research organization focused on providing
integrated and cost effective clinical development services that help the
pharmaceutical industry introduce new drug products rapidly from laboratory
to the market. Holmes is also actively involved in developing new drugs and
drug delivery systems. Currently, clinics operate in Omaha, Nebraska and
Toronto, Canada. For more information about the company please visit our
website at www.holmesbiopharma.com.

On behalf of the Board of Directors 

John F. Metcalfe, President

Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All information
contained in this press release should be independently investigated. This
press release contains forward-looking statements. These remarks involve
risks and uncertainties.  Risks are not limited to quarterly fluctuations
in results or the companies’ management of growth and competition. Other
risks are detailed in the Company's SEC filings.  Actual results may differ
materially from such information set forth herein.

Contact:
John F. Metcalfe, President and CEO  
www.holmesbiopharma.com
Tel: 001-877-241-4779 Email: ir@holmesbiopharma.com
DGAP 08.08.2007 
----------------------------------------------------------------------